Genetic and non-genetic determinants of raltegravir penetration into cerebrospinal fluid: A single arm pharmacokinetic study

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Johnson, Daniel H ^a   Sutherland, Deborah ^a   Acosta, Edward P ^c   Erdem, Husamettin ^a   Richardson, Danielle ^b   Haas, David W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; PROTEIN VARIANT; RALTEGRAVIR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; CEREBROSPINAL FLUID; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EXPOSURE; DRUG PENETRATION; FEMALE; GENE EXPRESSION; HOMOZYGOTE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHARMACOGENETICS; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; BLOOD-BRAIN BARRIER; FEMALE; GENETIC ASSOCIATION STUDIES; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PERMEABILITY; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRROLIDINONES; RISK FACTORS;

EID: 84892621348     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0082672     Document Type: Article

References (56)

1. Goudsmit J, de Wolf F, Paul DA, Epstein LG, Lange JM et al. (1986) Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection. Lancet 2: 177-180. PubMed: 2873436.
2. Davis LE, Hjelle BL, Miller VE, Palmer DL, Llewellyn AL et al. (1992) Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology 42: 1736-1739. doi:10.1212/WNL.42.9.1736. PubMed: 1513462.
3. Resnick L, Berger JR, Shapshak P, Tourtellotte WW (1988) Early penetration of the blood-brain-barrier by HIV. Neurology 38: 9-14. doi: 10.1212/WNL.38.1.9. PubMed: 3422110.
4. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D et al. (2008) Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65: 65-70. doi:10.1001/archneurol.2007.31. PubMed: 18195140.
5. Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ et al. (2011) Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 25: 357-365. doi:10.1097/QAD. 0b013e32834171f8. PubMed: 21124201.
6. Panel on Antiretroviral Guidelines for Adults and Adolescents (2012) Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services.
7. Croteau D, Letendre S, Best BM, Ellis RJ, Breidinger S et al. (2010) Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother 54: 5156-5160. doi:10.1128/AAC.00507-10. PubMed: 20876368.
8. Yilmaz A, Gisslén M, Spudich S, Lee E, Jayewardene A et al. (2009) Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLOS ONE 4: e6877. doi:10.1371/journal.pone.0006877. PubMed: 19721718.
9. Dean M, Rzhetsky A, Allikmets R (2001) The human ATP-binding cassette (ABC) transporter superfamily. Genome Res 11: 1156-1166. Available online at: doi:10.1101/gr.GR-1649R PubMed: 11435397.
10. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ et al. (1998) The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101: 289-294. doi:10.1172/JCI1269. PubMed: 9435299.
11. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT et al. (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37: 3594-3601. doi:10.1021/bi972709x. PubMed: 9530286.
12. Hermann DM, Kilic E, Spudich A, Krämer SD, Wunderli-Allenspach H et al. (2006) Role of drug efflux carriers in the healthy and diseased brain. Ann Neurol 60: 489-498. doi:10.1002/ana.21012. PubMed: 17048260.
13. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97: 3473-3478. doi:10.1073/pnas.97.7.3473. PubMed: 10716719.
14. Takane H, Kobayashi D, Hirota T, Kigawa J, Terakawa N et al. (2004) Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1). Gene - Journal of Pharmacology and Experimental Therapeutics 311: 1179-1187. doi: 10.1124/jpet.104.069724.
15. Marzolini C, Paus E, Buclin T, Kim RB (2004) Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 75: 13-33. doi:10.1016/j.clpt.2003.11.048. PubMed: 14749689.
16. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM et al. (2007) A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528. doi:10.1126/science.1135308. PubMed: 17185560.
17. Sauer G, Kafka A, Grundmann R, Kreienberg R, Zeillinger R et al. (2002) Basal expression of the multidrug resistance gene 1 (MDR-1) is associated with the TT genotype at the polymorphic site C3435T in mammary and ovarian carcinoma cell lines. Cancer Lett 185: 79-85. doi:10.1016/S0304-3835(02)00232-X. PubMed: 12142082.
18. Wang D, Johnson AD, Papp AC, Kroetz DL, Sadée W (2005) Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability. Pharmacogenet Genomics 15: 693-704. doi: 10.1097/01.fpc.0000178311. 02878.83. PubMed: 16141795.
19. Hitzl M, Drescher S, van der Kuip H, Schäffeler E, Fischer J et al. (2001) The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11: 293-298. doi: 10.1097/00008571-200106000-00003. PubMed: 11434506.
20. Dey S (2006) Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition. Expert Opin Drug Deliv 3: 23-35. doi:10.1517/17425247.3.1.23. PubMed: 16370938.
21. Owen A, Goldring C, Morgan P, Chadwick D, Park BK et al. (2005) Relationship between the C3435T and G2677T(A) polymorphisms in the ABCB1 gene and P-glycoprotein expression in human liver. Br J Clin Pharmacol 59: 365-370. doi:10.1111/j.1365-2125.2005.02229.x. PubMed: 15752383.
22. Coller JK, Barratt DT, Dahlen K, Loennechen MH, Somogyi AA (2006) ABCB1 genetic variability and methadone dosage requirements in opioid-dependent individuals. Clin Pharmacol Ther 80: 682-690. doi: 10.1016/j.clpt.2006.09.011. PubMed: 17178268.
23. Basic S, Hajnsek S, Bozina N, Filipcic I, Sporis D et al. (2008) The influence of C3435T polymorphism of ABCB1 gene on penetration of phenobarbital across the blood-brain barrier in patients with generalized epilepsy. Seizure 17: 524-530. doi:10.1016/j.seizure. 2008.01.003. PubMed: 18329296.
24. Siddiqui A, Kerb R, Weale ME, Brinkmann U, Smith A et al. (2003) Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 348: 1442-1448. doi: 10.1056/NEJMoa021986. PubMed: 12686700.
25. Haerian BS, Roslan H, Raymond AA, Tan CT, Lim KS et al. (2010) ABCB1 C3435T polymorphism and the risk of resistance to antiepileptic drugs in epilepsy: a systematic review and meta-analysis. Seizure 19: 339-346. doi:10.1016/j.seizure.2010.05.004. PubMed: 20605481.
26. Reference SNP (refSNP) Cluster Report: rs1045642 dbSNP. Available: http://www.ncbi.nlm.nih.gov/projects/SNP/snp-ref.cgi?rs=1045642. Accessed 28 May 2013
27. Chinn LW, Kroetz DL (2007) ABCB1 pharmacogenetics: progress, pitfalls, and promise. Clin Pharmacol Ther 81: 265-269. doi:10.1038/sj.clpt.6100052. PubMed: 17259950.
28. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmöller J et al. (2000) Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 97: 3473-3478. doi:10.1073/pnas.97.7.3473. PubMed: 10716719.
29. Moss DM, Kwan WS, Liptrott NJ, Smith DL, Siccardi M et al. (2011) Raltegravir is a substrate for SLC22A6: a putative mechanism for the interaction between raltegravir and tenofovir. Antimicrob Agents Chemother 55: 879-887. doi:10.1128/AAC.00623-10. PubMed: 21078936.
30. Cianfriglia M, Dupuis ML, Galluzzo CM, Palmisano L (19-22 July 2009). Interaction of the HIV integrase inhibitor raltegravir with the multidrug transporter P-glycoprotein (MDR1-Pgp) in human MDR Cells.; 2009. Cape Town, South Africa.
31. Haldar T, Ghosh S. (2012) Effect of population stratification on false positive rates of population-based association analyses of quantitative traits. Ann Hum Genet 76: 237-245. doi:10.1111/j. 1469-1809.2012.00708.x. PubMed: 22497479.
32. Deeken JF, Löscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13: 1663-1674. doi:10.1158/1078-0432.CCR-06-2854. PubMed: 17363519.
33. Urquhart BL, Kim RB (2009) Blood-brain barrier transporters and response to CNS-active drugs. Eur J Clin Pharmacol 65: 1063-1070. doi:10.1007/s00228-009- 0714-8. PubMed: 19727692.
34. Nies AT (2007) The role of membrane transporters in drug delivery to brain tumors. Cancer Lett 254: 11-29. doi:10.1016/j.canlet.2006.12.023. PubMed: 17275180.
35. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R et al. (2001) Integrating genotype and phenotype information: an overview of the PharmGKB project. Pharmacogenetics Research Network and Knowledge Base. Pharmacogenomics J 1: 167-170. doi:10.1038/sj.tpj.6500035. PubMed: 11908751.
36. Flicek P, Amode MR, Barrell D, Beal K, Brent S et al. (2011) Ensembl 2011. Nucleic Acids Res 39: D800-D806. doi:10.1093/nar/gkq1064. PubMed: 21045057.
37. Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE et al. (2009) Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 72: 310-316. doi: 10.1212/01.wnl.0000327823.81237. d1. PubMed: 18987351.
38. Saccone SF, Quan J, Mehta G, Bolze R, Thomas P et al. (2011) New tools and methods for direct programmatic access to the dbSNP relational database. Nucleic Acids Res 39: D901-D907. doi: 10.1093/nar/gkq1054. PubMed: 21037260.
39. Long MC, Bennetto-Hood C, Acosta EP (2008) A sensitive HPLC-MS-MS method for the determination of raltegravir in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 867: 165-171. doi: 10.1016/j.jchromb.2008.03.022. PubMed: 18430616.
40. Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS et al. (2008) Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLOS ONE 3: e3583. doi:10.1371/journal.pone.0003583. PubMed: 18974833.
41. Westfall PH, Young SS (1993) Resampling-based multiple testing : examples and methods for P-value adjustment. xvii. New York: Wiley. 340 pp.
42. Lanktree MB, Anand SS, Yusuf S, Hegele RA (2009) Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. J Lipid Res 50: 1487-1496. doi:10.1194/jlr.P900008-JLR200. PubMed: 19299407.
43. R-Core-Team (2011). R: A Language and Environment for Statistical Computing.
44. Ahonen A, Myllylä VV, Hokkanen E (1978) Measurement of reference values for certain proteins in cerebrospinal fluid. Acta Neurol Scand 58: 358-365. PubMed: 105562.
45. Haas DW, Johnson B, Nicotera J, Bailey VL, Harris VL et al. (2003) Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob Agents Chemother 47: 2131-2137. doi: 10.1128/AAC.47.7.2131- 2137.2003. PubMed: 12821458.
46. Haas DW, Stone J, Clough LA, Johnson B, Spearman P et al. (2000) Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection. Clin Pharmacol Ther 68: 367-374. doi:10.1067/mcp. 2000.109391. PubMed: 11061576.
47. Zhu D, Taguchi-Nakamura H, Goto M, Odawara T, Nakamura T et al. (2004) Influence of single-nucleotide polymorphisms in the multidrug resistance-1 gene on the cellular export of nelfinavir and its clinical implication for highly active antiretroviral therapy. Antivir Ther 9: 929-935. PubMed: 15651752.
48. Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M et al. (2002) MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol 53: 526-534. doi:10.1046/j. 1365-2125.2002.01591.x. PubMed: 11994059.
49. Rodriguez NS, Barreiro P, Rendón A, Barrios A, Corral A et al. (2006) Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C - T polymorphism at the multidrug resistance gene 1. Clinical Infectious Diseases 42: 291-295. doi:10.1086/499056. PubMed: 16355344.
50. Asano T, Takahashi KA, Fujioka M, Inoue S, Okamoto M et al. (2003) ABCB1 C3435T and G2677T/A polymorphism decreased the risk for steroid-induced osteonecrosis of the femoral head after kidney transplantation. Pharmacogenetics 13: 675-682. doi: 10.1097/00008571-200311000-00003. PubMed: 14583680.
51. Pauli-Magnus C, Feiner J, Brett C, Lin E, Kroetz DL (2003) No effect of MDR1 C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther 74: 487-498. doi:10.1016/S0009-9236(03)00234-0. PubMed: 14586389.
52. Haas DW, Wu H, Li H, Bosch RJ, Lederman MM et al. (2003) MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr 34: 295-298. doi:10.1097/00126334-200311010-00006. PubMed: 14600574.
53. Mai I, Perloff ES, Bauer S, Goldammer M, Johne A et al. (2004) MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol 58: 548-553. doi:10.1111/j.1365-2125.2004.02182.x. PubMed: 15521904.
54. Haas DW, Smeaton LM, Shafer RW, Robbins GK, Morse GD et al. (2005) Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis 192: 1931-1942. doi:10.1086/497610. PubMed: 16267764.
55. Kwan P, Baum L, Wong V, Ng PW, Lui CH et al. (2007) Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy and Behavior 11: 112-117.
56. Hung CC, Jen Tai J, Kao PJ, Lin MS, Liou HH (2007) Association of polymorphisms in NR1I2 and ABCB1 genes with epilepsy treatment responses. Pharmacogenomics 8: 1151-1158. doi: 10.2217/14622416.8.9.1151. PubMed: 17924830.